Pathological role of fractalkine/CX3CL1 in rheumatic diseases: A unique chemokine with multiple functions

Frontiers in Immunology

Volumn 2, Issue JAN, 2012, Pages

  Jones, Brian ^a   Koch, Alisa E ^b,c   Ahmed, Salahuddin ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Veterans Administration   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ADAM10; ADAM17 TACE; Fractalkine CX3CL1; Proteolytic shedding; Rheumatic disorders

Indexed keywords

EID: 84874048174     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2011.00082     Document Type: Review

References (79)

1. Ahmed, S., Marotte, H., Kwan, K., Ruth, J. H., Campbell, P. L., Rabquer, B. J., Pakozdi, A., and Koch, A. E. (2008). Epigallocatechin3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc. Natl. Acad. Sci. U.S.A. 105, 14692-14697.
2. Aries, P. M., Lamprecht, P., and Gross, W. L. (2007). Biological therapies: new treatment options for ANCA-associated vasculitis? Expert Opin. Biol. Ther. 7, 521-533.
3. Baggiolini, M., Dewald, B., and Moser, B. (1994). Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv. Immunol. 55, 97-179.
4. Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., and Schall, T. J. (1997). A new class of membrane-bound chemokine with a CX3C motif. Nature 385, 640-644.
5. Becker, Y. (2007). The spreading of HIV1 infection in the human organism is caused by fractalkine trafficking of theinfectedlymphocytes-areview, hypothesis and implications for treatment. Virus Genes 34, 93-109.
6. Brasier, A. R. (2006). The NF-kappaB regulatory network. Cardiovasc. Toxicol. 6, 111-130.
7. Charo, I. F., and Ransohoff, R. M. (2006). The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354, 610-621.
8. Chen, T., Guo, Z. P., Jiao, X. Y., Jia, R. Z., Zhang, Y. H., Li, J. Y., Huang, X. L., and Liu, H. J. (2011). Peoniflorin suppresses tumor necrosis factoralpha induced chemokine production in human dermal microvascular endothelial cells by blocking nuclear factor-kappaB and ERK pathway. Arch. Dermatol. Res. 303, 351-360.
9. Combadiere, C., Potteaux, S., Gao, J. L., Esposito, B., Casanova, S., Lee, E. J., Debre, P., Tedgui, A., Murphy, P. M., and Mallat, Z. (2003). Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107, 1009-1016.
10. Cypiene, A., Dadoniene, J., Rugiene, R., Ryliskyte, L., Kovaite, M., Petrulioniene, Z., Venalis, A., and Laucevicius, A. (2010). The influence of mean blood pressure on arterial stiffening and endothelial dysfunction in women with rheumatoid arthritis and systemic lupus erythematosus. Medicina (Kaunas) 46, 522-530.
11. Delaleu, N., and Jonsson, R. (2008). Altered fractalkine cleavage results in an organ-specific 17 kDa fractalkine fragment in salivary glands of NOD mice. Arthritis Res. Ther. 10, 114.
12. Denes, A., Ferenczi, S., Halasz, J., Kornyei, Z., and Kovacs, K. J. (2008). Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J. Cereb. Blood Flow Metab. 28, 1707-1721.
13. Di Bartolo, B. A., Nicholls, S. J., Bao, S., Rye, K. A., Heather, A. K., Barter, P. J., and Bursill, C. (2011). The apolipoprotein A-I mimetic peptide ETC-642 exhibits antiinflammatory properties that are comparable to high density lipoproteins. Atherosclerosis 217, 395-400.
14. Duthey, B., Hubner, A., Diehl, S., Boehncke, S., Pfeffer, J., and Boehncke, W. H. (2010). Antiinflammatory effects of the GABA(BM) receptor agonist baclofen in allergic contact dermatitis. Exp. Dermatol. 19, 661-666.
15. Eccles, R., Meier, C., Jawad, M., Weinmullner, R., Grassauer, A., and Prieschl-Grassauer, E. (2010). Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebocontrolled exploratory study in volunteers with early symptoms of the common cold. Respir. Res. 11, 108.
16. Escher, F., Vetter, R., Kuhl, U., Westermann, D., Schultheiss, H. P., and Tschope, C. (2011). Fractalkine in human inflammatory cardiomyopathy. Heart 97, 733-739.
17. Feldmann, M., and Maini, R. N. (2001). Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19, 163-196.
18. Fraticelli, P., Sironi, M., Bianchi, G., D'ambrosio, D., Albanesi, C., Stoppacciaro, A., Chieppa, M., Allavena, P., Ruco, L., Girolomoni, G., Sinigaglia, F., Vecchi, A., and Mantovani, A. (2001). Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J. Clin. Invest. 107, 1173-1181.
19. Gabrielli, A., Avvedimento, E. V., and Krieg, T. (2009). Scleroderma. N. Engl.J.Med.360, 1989-2003.
20. Garcia, G. E., Xia, Y., Chen, S., Wang, Y., Ye, R. D., Harrison, J. K., Bacon, K. B., Zerwes, H. G., and Feng, L. (2000). NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J. Leukoc. Biol. 67, 577-584.
21. Garton, K. J., Gough, P. J., Blobel, C. P., Murphy, G., Greaves, D. R., Dempsey, P. J., and Raines, E. W. (2001). Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276, 37993-38001.
22. Genta, M. S., Genta, R. M., and Gabay, C. (2006). Systemic rheumatoid vasculitis: a review. Semin. Arthritis Rheum. 36, 88-98.
23. Hasegawa, H., Kakuguchi, W., Kuroshima, T., Kitamura, T., Tanaka, S., Kitagawa, Y., Totsuka, Y., Shindoh, M., and Higashino, F. (2009). HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells. Br. J. Cancer 100, 1943-1948.
24. Hasegawa, M., Sato, S., Echigo, T., Hamaguchi, Y., Yasui, M., and Takehara,K. (2005). Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann. Rheum. Dis. 64, 21-28.
25. Hundhausen, C., Misztela, D., Berkhout, T. A., Broadway, N., Saftig, P., Reiss, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V., Kallen, K. J., Rose-John, S., and Ludwig, A. (2003). The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1mediated cell-cell adhesion. Blood 102, 1186-1195.
26. Hundhausen, C., Schulte, A., Schulz, B., Andrzejewski, M. G., Schwarz, N., Von Hundelshausen, P., Winter, U., Paliga, K., Reiss, K., Saftig, P., Weber, C., and Ludwig, A. (2007). Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J. Immunol. 178, 8064-8072.
27. Ikejima, H., Imanishi, T., Tsujioka, H., Kashiwagi, M., Kuroi, A., Tanimoto, T., Kitabata, H., Ishibashi, K., Komukai, K., Takeshita, T., and Akasaka, T. (2010). Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ. J. 74, 337-345.
28. Inoue, A., Hasegawa, H., Kohno, M., Ito, M. R., Terada, M., Imai, T., Yoshie, O., Nose, M., and Fujita, S. (2005). Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 52, 1522-1533.
29. Iwamoto, T., Okamoto, H., Toyama, Y., and Momohara, S. (2008). Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J. 275, 4448-4455.
30. Jiang, D. Q., Liu, H., Zhang, S. B., and Zhang, X. L. (2009). Aspirin inhibits tumor necrosis factor-alpha-stimulated fractalkine expression in human umbilical vein endothelial cells. Chin. Med. J. 122, 1147-1153.
31. Jones, B. A., Beamer, M., and Ahmed, S. (2010). Fractalkine/CX3CL1: a potential new target for inflammatory diseases. Mol. Interv. 10, 263-270.
32. Klosowska, K., Volin, M. V., Huynh, N., Chong, K. K., Halloran, M. M., and Woods, J. M. (2009). Fractalkine functions as a chemoattractant for osteoarthritis synovial fibroblasts and stimulates phosphorylation of mitogen-activated protein kinases and Akt. Clin. Exp. Immunol. 156, 312-319.
33. Koch, A. E. (2005). Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum. 52, 710-721.
34. Kruszka, P., and O'Brian, R. J. (2009). Diagnosis and management of Sjogren syndrome. Am. Fam. Physician 79, 465-470.
35. Lanier, L. L., Corliss, B., and Phillips, J. H. (1997). Arousal and inhibition of human NK cells. Immunol. Rev. 155, 145-154.
36. Lee, A. S., Jung, Y. J., Kim, D. H., Lee, T. H., Kang, K. P., Lee, S., Lee, N. H., Sung, M. J., Kwon, D. Y., Park, S. K., and Kim, W. (2009). Epigallocatechin3-O-gallate decreases tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells by suppressing NF-kappaB. Cell. Physiol. Biochem. 24, 503-510.
37. Lesnik, P., Haskell, C. A., and Charo, I. F. (2003). Decreased atherosclerosis in CX3CR1-/mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111, 333-340.
38. Li, F., Wang, Z., Liu, Y., and Li, J. (2010a). Down-regulation of fractalkine inhibits the in vitro and in vivo angiogenesis of the hepatocellular carcinoma HepG2 cells. Oncol. Rep. 24, 669-675.
39. Li, Y. M., Chen, Z. Q., Yao, X., Yang, A. Z., Li, A. S., Liu, D. M., and Gong, J. Q. (2010b). mRNA expression of chemokine receptors on peripheral blood mononuclear cells and correlation with clinical features in systemic lupus erythematosus patients. Chin. Med. Sci. J. 25, 162-168.
40. Lin, J., Ziring, D., Desai, S., Kim, S., Wong, M., Korin, Y., Braun, J., Reed, E., Gjertson, D., and Singh, R. R. (2008). TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin. Immunol. 126, 13-30.
41. Liuzzo, G., Vallejo, A. N., Kopecky, S. L., Frye, R. L., Holmes, D. R., Goronzy, J. J., and Weyand, C. M. (2001). Molecular fingerprint of interferongamma signaling in unstable angina. Circulation 103, 1509-1514.
42. Marasini, B., Cossutta, R., Selmi, C., Pozzi, M. R., Gardinali, M., Massarotti, M., Erario, M., Battaglioli, L., and Biondi, M. L. (2005). Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension. Clin. Dev. Immunol. 12, 275-279.
43. Marchesi, F., Locatelli, M., Solinas, G., Erreni, M., Allavena, P., and Mantovani, A. (2010). Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J. Neuroimmunol. 224, 39-44.
44. Matsumiya, T., Ota, K., Imaizumi, T., Yoshida, H., Kimura, H., and Satoh, K. (2010). Characterization of synergistic induction of CX3CL1/fractalkine by TNFalpha and IFN-gamma in vascular endothelial cells: an essential role for TNF-alpha in post-transcriptional regulation of CX3CL1. J. Immunol. 184, 4205-4214.
45. Matsunawa, M., Isozaki, T., Odai, T., Yajima, N., Takeuchi, H. T., Negishi, M., Ide, H., Adachi, M., and Kasama, T. (2006). Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum. 54, 3408-3416.
46. Moon, S. O., Kim, W., Sung, M. J., Lee, S., Kang, K. P., Kim, D. H., Lee, S. Y., So, J. N., and Park, S. K. (2006). Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells. Mol. Pharmacol. 70, 112-119.
47. Nakatani, K., Yoshimoto, S., Iwano, M., Asai, O., Samejima, K., Sakan, H., Terada, M., Hasegawa, H., Nose, M., and Saito, Y. (2010). Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models. Am. J. Physiol. Renal Physiol. 299, F207- F216.
48. Nakayama, T., Watanabe, Y., Oiso, N., Higuchi, T., Shigeta, A., Mizuguchi, N., Katou, F., Hashimoto, K., Kawada, A., and Yoshie, O. (2010). Eotaxin-3/CC chemokine ligand 26 is a functional ligand for CX3CR1. J. Immunol. 185, 6472-6479.
49. Nanki, T., Imai, T., Nagasaka, K., Urasaki, Y., Nonomura, Y., Taniguchi, K., Hayashida, K., Hasegawa, J., Yoshie, O., and Miyasaka, N. (2002). Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 46, 2878-2883.
50. Nanki, T., Urasaki, Y., Imai, T., Nishimura, M., Muramoto, K., Kubota, T., and Miyasaka, N. (2004). Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J. Immunol. 173, 7010-7016.
51. Nishimura, M., Umehara, H., Nakayama, T.,Yoneda, O., Hieshima, K.,Kakizaki,M.,Dohmae,N.,Yoshie, O., and Imai, T. (2002). Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol. 168, 6173-6180.
52. Odai, T., Matsunawa, M., Takahashi, R., Wakabayashi, K., Isozaki, T., Yajima, N., Miwa, Y., and Kasama, T. (2009). Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis. J. Rheumatol. 36, 1158-1165.
53. Okamoto, H., Yamamura, M., Morita, Y., Harada, S., Makino, H., and Ota, Z. (1997). The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 40, 1096-1105.
54. Paludan, S. R. (2000). Synergistic action of pro-inflammatory agents: cellular and molecular aspects. J. Leukoc. Biol. 67, 18-25.
55. Pirvulescu, M. M., Gan, A. M., Stan, D., Simion, V., Calin, M., Butoi, E., Tirgoviste, C. I., and Manduteanu, I. (2011). Curcumin and a morus alba extract reduce proinflammatory effects of resistin in human endothelial cells. Phytother. Res. 25, 1737-1742.
56. Pope, R. M. (2002). Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev. Immunol. 2, 527-535.
57. Ramos-Casals, M., Tzioufas, A. G., Stone, J. H., Siso, A., and Bosch, X. (2010). Treatment of primary Sjogren syndrome: a systematic review. JAMA 304, 452-460.
58. Ruth, J. H., Volin, M. V., Haines, G. K. III, Woodruff, D. C., Katschke, K. J. Jr., Woods, J. M., Park, C. C., Morel, J. C., and Koch, A. E. (2001). Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 44, 1568-1581.
59. Sato, E., Iikuni, N., Yoshio, T., Minota, S., Kamatani, N., and Okamoto, H. (2006). Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus. Ann. Rheum. Dis. 65, 1257-1259.
60. Sawai, H., Park, Y. W., He, X., Goronzy, J. J., and Weyand, C. M. (2007). Fractalkine mediates T cell-dependent proliferation of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum. 56, 3215-3225.
61. Schroder, K., Hertzog, P. J., Ravasi, T., and Hume, D. A. (2004). Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75, 163-189.
62. Sciume,G.,Soriani,A.,Piccoli,M.,Frati, L., Santoni, A., and Bernardini, G. (2010). CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro-oncology 12, 701-710.
63. Scott, D. L., and Kingsley, G. H. (2006). Tumor necrosis factor inhibitors for rheumatoid arthritis. N.Engl.J.Med. 355, 704-712.
64. Sicinska, J., Gorska, E., Cicha, M., Kuklo-Kowalska, A., Hamze, V., Stepien, K., Wasik, M., and Rudnicka, L. (2008). Increased serum fractalkine in systemic sclerosis. Down-regulation by prostaglandin E1. Clin. Exp. Rheumatol. 26, 527-533.
65. Tanaka, Y., Adams, D. H., Hubscher, S., Hirano, H., Siebenlist, U., and Shaw, S. (1993). T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 361, 79-82.
66. Tsubota, K., Nishiyama, T., Mishima, K., Inoue, H., Doi, T., Hattori, Y., Kodama, T., Higuchi, A., Hayashi, Y., and Saito, I. (2009). The role of fractalkine as an accelerating factor on the autoimmune exocrinopathy in mice. Invest. Ophthalmol. Vis. Sci. 50, 4753-4760.
67. Turner, S. L., Mangnall, D., Bird, N. C., Blair-Zajdel, M. E., and Bunning, R. A. (2010). Effects of proinflammatory cytokines on the production of soluble fractalkine and ADAM17 by HepG2 cells. J. Gastrointestin. Liver Dis. 19, 265-271.
68. Umehara, H., Bloom, E., Okazaki, T., Domae, N., and Imai, T. (2001). Fractalkine and vascular injury. Trends Immunol. 22, 602-607.
69. Umehara, H., Bloom, E. T., Okazaki, T., Nagano, Y., Yoshie, O., and Imai, T. (2004). Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler. Thromb. Vasc. Biol. 24, 34-40.
70. Umehara, H., Tanaka, M., Sawaki, T., Jin, Z. X., Huang, C. R., Dong, L., Kawanami, T., Karasawa, H., Masaki,Y., Fukushima, T., Hirose,Y., and Okazaki, T. (2006). Fractalkine in rheumatoid arthritis and allied conditions. Mod. Rheumatol. 16, 124-130.
71. Volin, M. V., Huynh, N., Klosowska, K., Chong, K. K., and Woods, J. M. (2007). Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum. 56, 2512-2522.
72. Volin, M. V., Woods, J. M., Amin, M. A., Connors, M. A., Harlow, L. A., and Koch, A. E. (2001). Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am. J. Pathol. 159, 1521-1530.
73. Wan, Y., and Evans, R. M. (2010). Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J. Mol. Endocrinol. 44, 135-142.
74. Wang, W., Wang, Y. L., Chen, X. Y., Li, Y. T., Hao, W., Jin, Y. P., and Han, B. (2011). Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol. Biol. Rep. 38, 3277-3284.
75. Wiener, J. J., Sun, S., and Thurmond, R. L. (2010). Recent advances in the design of cathepsin S inhibitors. Curr. Top. Med. Chem. 10, 717-732.
76. Wildenberg, M. E., Van HeldenMeeuwsen, C. G., Drexhage, H. A., and Versnel, M. A. (2008). Altered fractalkine cleavage potentially promotes local inflammation in NOD salivary gland. Arthritis Res. Ther. 10, R69.
77. Yajima, N., Kasama, T., Isozaki, T., Odai, T., Matsunawa, M., Negishi, M., Ide, H., Kameoka, Y., Hirohata, S., and Adachi, M. (2005). Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 52, 1670-1675.
78. Yoneda, O., Imai, T., Goda, S., Inoue, H., Yamauchi, A., Okazaki, T., Imai, H., Yoshie, O., Bloom, E. T., Domae, N., and Umehara, H. (2000). Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164, 4055-4062.
79. Yoshida, H., Imaizumi, T., Fujimoto, K., Matsuo, N., Kimura, K., Cui, X., Matsumiya, T., Tanji, K., Shibata, T., Tamo, W., Kumagai, M., and Satoh, K. (2001). Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. Neurosci. Lett. 303, 132-136.